Managed care implications of hereditary angioedema

American Journal of Managed Care

Volumn 19, Issue 7 SUPPL, 2013, Pages

  Cardarelli, William ^a  

^a HARVARD VANGUARD MEDICAL ASSOCIATES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C1S INHIBITOR; ECALLANTIDE; ICATIBANT;

ANGIONEUROTIC EDEMA; ARTICLE; CHRONIC DISEASE; DIAGNOSTIC ERROR; DRUG COST; HEALTH CARE COST; HOME CARE; HUMAN; MAJOR CLINICAL STUDY; MANAGED CARE; PRIORITY JOURNAL; REIMBURSEMENT; TREATMENT OUTCOME; ADOLESCENT; ADULT; AGED; ANGIOEDEMAS, HEREDITARY; CHILD; COST OF ILLNESS; DELAYED DIAGNOSIS; ECONOMICS; FEMALE; HEALTH CARE SURVEY; HEALTH INSURANCE; INFANT; MALE; MIDDLE AGED; PRESCHOOL CHILD; QUALITY OF LIFE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANGIOEDEMAS, HEREDITARY; CHILD; CHILD, PRESCHOOL; COST OF ILLNESS; DELAYED DIAGNOSIS; DIAGNOSTIC ERRORS; FEMALE; HEALTH CARE SURVEYS; HEALTH EXPENDITURES; HOME CARE SERVICES; HUMANS; INFANT; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; QUALITY OF LIFE; YOUNG ADULT;

EID: 84899469158     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Zuraw BL. Hereditary angioedema. N Engl J Med. 2008;359:1027-1036.
2. Morgan BP. Hereditary angiogedema - therapies old and new. N Engl J Med. 2010;363:581-583.
3. Bork K, Ressel N. Sudden upper airway obstruction in patients with hereditary angioedema. Transfus Apher Sci. 2003;29:235- 238.
4. Lumry WR, Castaldo AJ, Vernon MK, Blaustein MB, Wilson DA, Horn PT. The humanistic burden of hereditary angioedema: impact on health-related quality of life, productivity, and depression. Allergy Asthma Proc. 2010;31:407-414.
5. Lunn M, Banta E. Ecallantide for the treatment of hereditary angioedema in adults. Clin Med Insights Cardiol. 2011;5:49-54.
6. Roche O, Blanch A, Caballero T, Sastre N, Callejo D, López- Trascasa M. Hereditary angiogedema due to C1 inhibitor deficiency: patient registry and approach to the prevalence in Spain. Ann Allergy Asthma Immunol. 2005;94:498-503. (Pubitemid 40547939)
7. Riedl M, Gower RG, Chrvala CA. Current medical management of hereditary angioedema: results from a large survey of US physicians. Ann Allergy Asthma Immunol. 2011;106:316-322.
8. Huang S-W. Results of an on-line survey of patients with hereditary angioedema. Allergy Asthma Proc. 2004;25:127-131. (Pubitemid 38639027)
9. Lunn ML, Santos CB, Craig TJ. Is there a need for clinical guidelines in the United States for the diagnosis of hereditary angioedema and the screening of family members of affected patients? Ann Allergy Asthma Immunol. 2010;104:211;214.
10. Bowie KJ, Scarupa H, Li H; Institute for Asthma & Allergy, PC. Unnecessary abdominal surgeries secondary to undiagnosed hereditary angioedema. J Allergy Clin Immunol. 2007;S276:Abstr 1082.
11. Wilson DA, Bork K, Shea EP, Rentz AM, Blaustein MB, Pullman WE. Economic costs associated with acute attacks and long-term management of hereditary angioedema. Ann Allergy Asthma Immunol. 2010;104:314-320.
12. US Food and Drug Administration (FDA). October 10, 2008 Approval Letter-Cinryze. http://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ ApprovedProducts/LicensedProducts BLAs/FractionatedPlasmaProducts/ucm093602.htm. Accessed December 16, 2012.
13. US Food and Drug Administration (FDA). FDA approves Berinert to treat abdominal attacks, facial swelling associated with hereditary angioedema. FDA website. http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/2009/ ucm186257.htm. Accessed December 16, 2012.
14. US Food and Drug Administration (FDA). FDA approves Kalbitor for treating potentially life-threatening attacks of hereditary angioedema. FDA website. http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ucm192687.htm. Accessed December 17, 2012
15. Firazyr [full prescribing information]. Lexington MA: Shire Orphan Therapies, Inc; 2011.
16. RegenenceRx. Therapeutic class review: biologic agents for management of hereditary angioedema (updated for Berinert and Kalbitor), April 2010.
17. Zilberberg MD, Jacobsen T, Tillotson G. The burden of hospitalizations and emergency department visits with hereditary angioedema and angioedema in the United States, 2007. Allergy Asthma Proc. 2010;31(6):511-519.
18. Longhurst HJ, Farkas H, Craig T, et al. HAE international home therapy consensus document. Allergy Asthma Clin Immunol. 2010;6:22.
19. Landmesser LM, Mariano D. Impact of a self-administration training and support program on site of care in patients with hereditary angioedema receiving nanofiltered C1 esterase inhibitor for routine prophylaxis. J Manag Care Pharm. 2012;18(7):549.
20. Patients with life-threatening hereditary angioedema [press release]. April 26, 2012. http://news.walgreens.com/article-display. cfm?article-id=5583.
21. Bowen T, Cicardi M, Farkas H, et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol. 2010;6(1):24.